Literature DB >> 27477529

Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.

Jeffrey J Tosoian1, Fawaz Almutairi2, Carlos L Morais2, Stephanie Glavaris1, Jessica Hicks2, Debasish Sundi3, Elizabeth Humphreys1, Misop Han1, Angelo M De Marzo2, Ashley E Ross1, Scott A Tomlins4, Edward M Schaeffer5, Bruce J Trock1, Tamara L Lotan6.   

Abstract

African-American (AA) men have a higher risk of lethal prostate cancer (PCa) compared to European-American (EA) men. However, the molecular basis of this difference, if any, remains unclear. In EA PCa, PTEN loss, but not ERG rearrangement, has been associated with poor outcomes in most studies. Although ERG rearrangement is less common in AA compared to EA PCa, the relative frequency of PTEN loss and the association of PTEN/ERG molecular subtypes with outcomes is unknown for AA PCa. We examined PTEN/ERG status by immunohistochemistry in self-identified AA patients undergoing radical prostatectomy at Johns Hopkins with tumor tissue available on tissue microarray (TMA; n=169) and matched these cases by pathologic parameters to 169 EA patients from the same TMAs. The rate of PTEN loss was significantly lower in AA compared to EA PCa (18% vs 34%; p=0.001), similar to the lower rate of ERG expression (25% vs 51%; p<0.001). To examine the association of PTEN/ERG status with oncologic outcomes, we created an additional TMA of 87 AA tumors with Gleason score > 4 + 3 = 7. Among the total population of AA men with outcome data from all TMAs (n=222), PTEN loss was associated with higher risk of biochemical recurrence (hazard ratio [HR] 2.25, 95% confidence interval [CI] 1.33-3.82) and metastasis (HR 3.90, 95% CI 1.46-10.4) in multivariable models. PATIENT
SUMMARY: PTEN and ERG alterations in prostate cancer are less likely in African-American than in European-American men. However, PTEN loss remains associated with poor prostate cancer outcomes among African-American men.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  African-American; Biomarker; ERG; European-American; Immunohistochemistry; PTEN; Prostatic carcinoma; Race; Radical prostatectomy

Mesh:

Substances:

Year:  2016        PMID: 27477529      PMCID: PMC5274596          DOI: 10.1016/j.eururo.2016.07.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Authors:  Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou
Journal:  Prostate       Date:  2010-09-28       Impact factor: 4.104

3.  Mutational Landscape of Aggressive Prostate Tumors in African American Men.

Authors:  Karla J Lindquist; Pamela L Paris; Thomas J Hoffmann; Niall J Cardin; Rémi Kazma; Joel A Mefford; Jeffrey P Simko; Vy Ngo; Yalei Chen; Albert M Levin; Dhananjay Chitale; Brian T Helfand; William J Catalona; Benjamin A Rybicki; John S Witte
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

4.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

5.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

Review 6.  Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography.

Authors:  Daniel S W Tan; Tony S K Mok; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2015-11-17       Impact factor: 44.544

7.  Evidence for molecular differences in prostate cancer between African American and Caucasian men.

Authors:  Francesca Khani; Juan Miguel Mosquera; Kyung Park; Mirjam Blattner; Catherine O'Reilly; Theresa Y MacDonald; Zhengming Chen; Abhishek Srivastava; Ashutosh K Tewari; Christopher E Barbieri; Mark A Rubin; Brian D Robinson
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

Review 8.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22

9.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

10.  A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.

Authors:  Gyorgy Petrovics; Hua Li; Tanja Stümpel; Shyh-Han Tan; Denise Young; Shilpa Katta; Qiyuan Li; Kai Ying; Bernward Klocke; Lakshmi Ravindranath; Indu Kohaar; Yongmei Chen; Dezső Ribli; Korbinian Grote; Hua Zou; Joseph Cheng; Clifton L Dalgard; Shimin Zhang; István Csabai; Jacob Kagan; David Takeda; Massimo Loda; Sudhir Srivastava; Matthias Scherf; Martin Seifert; Timo Gaiser; David G McLeod; Zoltan Szallasi; Reinhard Ebner; Thomas Werner; Isabell A Sesterhenn; Matthew Freedman; Albert Dobi; Shiv Srivastava
Journal:  EBioMedicine       Date:  2015-10-31       Impact factor: 8.143

  10 in total
  41 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

2.  Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study.

Authors:  Erfan Amini; Tracy Campanelli Palmer; Jie Cai; Gary Lieskovsky; Siamak Daneshmand; Hooman Djaladat
Journal:  World J Urol       Date:  2018-03-13       Impact factor: 4.226

3.  TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Authors:  Harsimar B Kaur; Jiayun Lu; Liana B Guedes; Laneisha Maldonado; Logan Reitz; John R Barber; Angelo M De Marzo; Scott A Tomlins; Karen S Sfanos; Mario Eisenberger; Edward M Schaeffer; Corinne E Joshu; Tamara L Lotan
Journal:  Hum Pathol       Date:  2019-03-06       Impact factor: 3.466

Review 4.  Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans.

Authors:  Jacqueline Olender; Norman H Lee
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 5.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

Review 6.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

7.  The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.

Authors:  R Liu; J Zhou; S Xia; T Li
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

Review 8.  Analysis of Tumor Biology to Advance Cancer Health Disparity Research.

Authors:  Cheryl J Smith; Tsion Z Minas; Stefan Ambs
Journal:  Am J Pathol       Date:  2017-11-11       Impact factor: 4.307

9.  Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes.

Authors:  Christopher M Heaphy; Corinne E Joshu; John R Barber; Christine Davis; Reza Zarinshenas; Angelo M De Marzo; Tamara L Lotan; Karen S Sfanos; Alan K Meeker; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-08       Impact factor: 4.254

10.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Authors:  Franklin W Huang; Juan Miguel Mosquera; Andrea Garofalo; Coyin Oh; Maria Baco; Ali Amin-Mansour; Bokang Rabasha; Samira Bahl; Stephanie A Mullane; Brian D Robinson; Saud Aldubayan; Francesca Khani; Beerinder Karir; Eejung Kim; Jeremy Chimene-Weiss; Matan Hofree; Alessandro Romanel; Joseph R Osborne; Jong Wook Kim; Gissou Azabdaftari; Anna Woloszynska-Read; Karen Sfanos; Angelo M De Marzo; Francesca Demichelis; Stacey Gabriel; Eliezer M Van Allen; Jill Mesirov; Pablo Tamayo; Mark A Rubin; Isaac J Powell; Levi A Garraway
Journal:  Cancer Discov       Date:  2017-05-17       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.